Navigation Links
Discovery May Lead to Better Multiple Sclerosis Treatments
Date:3/29/2010

Lab study sheds light on why the most common drug may not work for all patients

MONDAY, March 29 (HealthDay News) -- There may be two types of multiple sclerosis and each may respond differently to treatment with the first-line drug commonly prescribed for the condition, new research suggests.

Among multiple sclerosis (MS) patients who take the popular drug, known as interferon beta, overall effectiveness is only fair, with about half of all patients experiencing an average one-third reduction in recurrences, according to researchers at Stanford University.

MS is an autoimmune disease that occurs when immune cells called T cells attack the protective myelin sheathing around the nerves of the central nervous system, resulting in symptoms such as paralysis and blindness.

In this study, which was performed in mice and human blood samples, investigators focused on two cytokines called gamma interferon and IL-17. Cytokines are chemicals used by immune cells to communicate.

The researchers found that treatment interferon beta benefited mice with MS induced by gamma-interferon-secreting T cells but worsened symptoms in mice with MS induced by IL-17-secreting T cells.

In the next phase of the study, the researchers found that human blood samples with low levels of a variety of IL-17, called IL-17F, responded well to interferon beta treatment while those with very high IL-17F levels (about one-third of patients) responded poorly to the drug.

The study results were published online March 28 in the journal Nature Medicine.

If the findings are confirmed in large human studies and by other laboratories, it could mean that MS patients might someday be able to have a blood test to determine whether they're likely to respond to treatment with interferon beta, senior study author Dr. Lawrence Steinman, a professor of neurology and neurological sciences at the Stanford University School of Medicine, stated in a university news release.

More information

The National Multiple Sclerosis Society has more about multiple sclerosis treatments.



-- Robert Preidt



SOURCE: Stanford University, news release, March 28, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Discovery of cellular switch may provide new means of triggering cell death, treating disease
2. U discovery gives insight into brain replay process
3. Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma
4. Effective prostate cancer treatment discovery
5. SeqWright Advances Genomic Discovery With Isilon IQ
6. New discovery: Plaice are spotted (on the inside)
7. UCSF enters drug discovery agreement with Genentech
8. UCSF Enters Drug Discovery Agreement with Genentech
9. Discovery Health and National Organization for Rare Disorders Partner for Second Annual Rare Disease Day With the Premiere of the Special DISEASE DETECTIVES
10. Discovery points way for new treatment for aneurysms: UBC-Providence Research
11. Discovery of mechanism in brain cell injury in Huntingtons offers new treatment approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: